金属有机框架负载siRNA克服乳腺癌基质屏障的研究
本研究构建了负载靶向ITGAV的siRNA的金属有机框架颗粒MOF@siITGAV,在4T1乳腺癌细胞及三阴性乳腺癌小鼠模型中验证其克服基质屏障、增强药物渗透和免疫可及性的效果。MOF@siITGAV可被4T1细胞摄取并释放siRNA,下调ITGAV表达和TGF-β1水平,增强3D球体穿透能力,给药15天后MOF@siITGAV组肿瘤体积小于空白对照组(P=0.025),肿瘤组织Ⅰ型胶原减少、CD8阳性细胞增多,主要脏器未见明显异常。
要点
- MOF@siITGAV粒径(198.0±3.3)nm,电位-(20.2±0.4)mV,可被4T1细胞摄取并释放siRNA。
- MOF@siITGAV组ITGAV表达为(46.5±11.3)%,低于空白对照组;TGF-β1为(388.4±14.4)pg/ml。
- 给药15天后MOF@siITGAV组肿瘤体积(135.3±41.9)mm3,小于空白对照组(691.1±193.0)mm3(P=0.025)。
核心结论
- 靶向癌细胞表面整合素αv可破坏细胞外基质,改善药物递送并增加免疫浸润。
研究设计与样本
- 构建MOF@siITGAV颗粒并表征,在乳腺癌4T1细胞系及三阴性乳腺癌小鼠模型中评价其摄取、毒性、基因沉默、穿透和抗肿瘤效果。
主要发现
- MOF@siITGAV粒径为(198.0±3.3)nm,zeta电位为-(20.2±0.4)mV。
- MOF@siITGAV组ITGAV表达为(46.5±11.3)%,游离siITGAV组为(109.9±19.0)%,均低于空白对照组。
- 空白对照组、游离siITGAV组和MOF@siITGAV组培养基TGF-β1分别为(474.5±34.4)pg/ml、(437.2±16.5)pg/ml和(388.4±14.4)pg/ml。
- 0、10、20、40、80和160 μg/ml MOF@siITGAV处理4T1细胞24 h后细胞活性分别为(99.7±3.5)%、(98.2±5.2)%、(97.3±6.6)%、(92.1±8.1)%和(92.4±4.1)%。
- 给药15 d后,空白对照组、MOF@siNC组和MOF@siITGAV组肿瘤体积分别为(691.1±193.0)mm3、(652.7±306.5)mm3和(135.3±41.9)mm3,MOF@siITGAV组小于空白对照组(P=0.025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to develop a new delivery strategy that utilized metal organic framework (MOF) loaded with small-interfering RNA (siRNA) targeting ITGAV to overcome tumor matrix barrier, and thus enhance drug penetration and immune accessibility in breast cancer. Methods: MOF@siITGAV particles were constructed and characterized. The uptake of MOF@siITGAV in breast cancer cell line 4T1 was observed by the cellular uptake assay. The toxicity of MOF@siITGAV was detected by cell counting kit 8 (CCK-8). The blank control group, naked siITGAV group and MOF@siITGAV group were set. Real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) and Western blot were used to detect the expressions of ITGAV. The level of transforming growth factor β1 (TGF-β1) in the cell culture medium was detected by enzyme-linked immunosorbent assay (ELISA). The penetration of MOF@siITGAV in 4T1 cells was tested by constructing 3D spheroids. Mouse models of triple negative breast cancer were established. The effect of MOF@siITGAV on the growth of transplanted tumors and main organs was verified. Imminohistochemical (IHC) was used to test the expression of collagen and CD8. Results: MOF@siITGAV particles were constructed with sizes of (198.0±3.3) nm and zeta potential of -(20.2±0.4) mV. MOF@siITGAV could be engulfed by 4T1 cells and triggered to release siRNA. Compared to the blank control group, the expression of ITGAV in the MOF@siITGAV group [(46.5±11.3)%] and the naked siITGAV group [(109.9±19.0)%] was lower. TGF-β1 in the cell culture medium of the blank control group, naked siITGAV group, and MOF@siITGAV group was (474.5±34.4) pg/ml, (437.2±16.5) pg/ml, and (388.4±14.4) pg/ml, respectively. MOF@siITGAV could better penetrate into 4T1 spheroids and exhibit no obvious toxicity. The cell viability was (99.7±3.5)%, (98.2±5.2)%, (97.3±6.6)%, (92.1±8.1)%, and (92.4±4.1)%, respectively, after MOF@siITGAV treatment with the concentration of 0, 10, 20, 40, 80, and 160 μg/ml, respectively, for 24 h. The tumor growth in the MOF@siITGAV group was suppressed significantly. After 15-day treatment, the tumor volume of the MOF@siITGAV group was (135.3±41.9) mm3, smaller than that of the blank control group [(691.1±193.0) mm3] (P=0.025). The expression of collagen and the number of CD8 positive cells of the MOF@siITGAV group were lower than those of the other two groups. No significant abnormalities were observed in the main organs of mice. Conclusions: Targeting the integrinαv on the surface of cancer cells could destroy extracellular matrix, improve drug delivery, and increase immune infiltration. 目的: 开发一种新型递送策略,利用金属有机框架(MOF)负载针对整合素αv(ITGAV)的小干扰RNA siITGAV,以克服基质屏障,进而增强乳腺癌内药物递送及免疫可及性。 方法: 构建MOF@siITGAV颗粒,对其进行材料表征。通过细胞摄取实验观察乳腺癌4T1细胞对MOF@siITGAV的摄取情况,细胞计数试剂盒8法检测MOF@siITGAV的细胞毒性。设空白对照组、游离siITGAV组和MOF@siITGAV组,采用实时荧光定量聚合酶链反应检测各组4T1细胞中ITGAV mRNA的表达,采用Western blot检测ITGAV蛋白的表达,采用酶联免疫吸附试验检测TGF-β1的含量。采用3D球体穿透实验观察MOF@siITGAV穿透4T1细胞球的能力。建立三阴性乳腺癌小鼠模型,观察MOF@siITGAV对移植瘤生长及小鼠心、肝、脾、肺、肾等主要脏器的影响,采用免疫组化染色检测肿瘤组织中Ⅰ型胶原蛋白和CD8的表达。 结果: 成功构建MOF@siITGAV颗粒,粒径为(198.0±3.3)nm,电位为-(20.2±0.4)mV。4T1细胞能有效摄取MOF@siITGAV,并触发siRNA的有效释放,MOF@siITGAV组细胞中ITGAV mRNA和蛋白表达水平、TGF-β1的表达水平均显著下调[相对于空白对照组,游离siITGAV组和MOF@siITGAV组4T1细胞中ITGAV mRNA相对表达水平分别为(109.9±19.0)%和(46.5±11.3)%;空白对照组、MOF@siNC组和MOF@siITGAV组TGF-β1浓度分别为(474.5±34.4)pg/ml、(437.2±16.5)pg/ml和(388.4±14.4)pg/ml]。MOF@siITGAV在4T1细胞球中的穿透能力更强,对4T1细胞无明显杀伤效应,0、10、20、40、80和160 μg/ml MOF@siITGAV分别处理4T1细胞24 h,细胞活性分别为(99.7±3.5)%、(98.2±5.2)%、(97.3±6.6)%、(92.1±8.1)%和(92.4±4.1)%。MOF@siITGAV能有效抑制小鼠乳腺癌移植瘤的生长,给药15 d后,空白对照组、MOF@siNC组和MOF@siITGAV组小鼠的肿瘤体积分别为(691.1±193.0)mm3、(652.7±306.5)mm3和(135.3±41.9)mm3,MOF@siITGAV组小鼠的肿瘤体积小于空白对照组(P=0.025)。与空白对照组和MOF@siNC组相比,MOF@siITGAV组小鼠肿瘤组织中Ⅰ型胶原蛋白的含量明显减少,CD8阳性细胞明显增多,心、肝、脾、肺、肾等主要脏器未见明显异常。 结论: ITGAV可以破坏乳腺癌的ECM,改善药物瘤内递送,促进免疫细胞浸润。.
引用
- Zeng C, Zhang J. [Study of metal organic framework with siRNA for overcoming matrix barrierin breast cancer]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 38742354. doi:10.3760/cma.j.cn112152-20230921-00153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。